CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(03): 317-323
DOI: 10.1055/s-0042-1748825
Original Article

Adaptation of a Public–Private Partnership Model for the Implementation of Minipool Nucleic Acid Testing for Screening Routine Blood Donations and Assay Evaluation

Smita Mahapatra
1   Department of Transfusion Medicine, Sri-Rama Chandra Bhanja Medical College & Hospital, Cuttack, Odisha, India
Pankaj Parida
1   Department of Transfusion Medicine, Sri-Rama Chandra Bhanja Medical College & Hospital, Cuttack, Odisha, India
Chitta Ranjan Prasad
2   Department of Transfusion Medicine, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, Odisha, India
Sabita Palai
4   Transfusion Medicine, Maharaja Krishna Chandra Gajapati Medical College Hospital, Berhampur, Odisha, India
Debashis Mishra
3   Blood Bank, Capital Hospital, Bhubaneswar, Odisha, India
Susmita Behera
4   Transfusion Medicine, Maharaja Krishna Chandra Gajapati Medical College Hospital, Berhampur, Odisha, India
Rabindra Kumar Mishra
4   Transfusion Medicine, Maharaja Krishna Chandra Gajapati Medical College Hospital, Berhampur, Odisha, India
Binayak Prasad Prusty
5   Central Red Cross Blood Bank, Cuttack, Odisha, India
Kalyan Sarkar
6   BMC Hospital, Bhubaneswar, Odisha, India
› Author Affiliations
Funding None.


Background Nucleic acid amplification testing (NAT) for the screening of blood donations is known to improve blood safety. The decision to initiate NAT requires careful deliberation of infrastructure, skilled manpower, and financial resources. This report outlines the initiative of the Government of Odisha to implement NAT screening in government blood banks in the state of Odisha, India, through public–private partnership (PPP) and evaluates the incremental yield of minipool NAT screening over serology testing of blood donations.

Methods Blood donations collected between June 2016 and September 2018 were initially screened for HBV (HBsAg), HCV (anti-HCV), and HIV (anti-HIV-1 and HIV-2) by ELISA, and syphilis and malaria. Sero-nonreactive donations were further screened in pools of six by Roche cobas TaqScreen MPX test version 2.0 (MPX2) NAT.

Results On screening 3,39,472 blood donations, 1.34% seroreactive donations were detected. In all, 847 NAT-reactive donations (0.26%): 693 HBV, 58 HCV, and 96 HIV were detected. The NAT yields were 1:386 overall, 1:472 for HBV, 1:5642 for HCV, and 1:3409 for HIV.

Conclusion NAT testing using the highly sensitive MPX2 assay leads to incremental detection of TTIs over serology. Implementation of NAT along with serological testing in blood centers all over India will be an important step towards providing safe blood. Our study not only highlights the benefits of minipool NAT testing but also presents a scalable PPP model that can serve as a template for application across other states.

Authors' Contributions

All the authors contributed to the concept, design, data collection, data analysis, interpretation of data, and critically reviewing the manuscript. All authors approved the final version of the manuscript.

Publication History

Article published online:
10 June 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 National AIDS Control Organisation (NACO). A Report on Rapid Situation Assessment of Blood Transfusion Services in India”. New Delhi: NACO 2014. 12.
  • 2 National AIDS Control Organisation (NACO). National Blood Transfusion Council (NBTC). Assessment of Blood Banks in India-2016. In: India MoHFW, ed. 2016:1–81;21–22
  • 3 Chaurasia R, Zaman S, Das B, Chatterjee K. Screening donated blood for transfusion transmitted infections by serology along with NAT and response rate to notification of reactive results: an Indian experience. J Blood Transfus 2014; 2014: 412105
  • 4 Shrivastava M, Mishra S. Nucleic acid amplification testing (NAT): an innovative diagnostic approach for enhancing blood safety. National Journal of Laboratory Medicine. 2017; 6 (02) IR01-IR6
  • 5 Pandey P, Tiwari AK, Dara RC, Rawat GS, Negi A, Raina V. Confirmation and follow up of initial “NAT yields”: Prospective study from a tertiary healthcare center in India. Transfus Apheresis Sci 2016; 54 (02) 242-247
  • 6 Hans R, Marwaha N. Nucleic acid testing-benefits and constraints. Asian J Transfus Sci 2014; 8 (01) 2-3
  • 7 Guidelines On Estimation Of Residual Risk Of Hiv WHO.. HBV or HCV infections via cellular blood components and plasma. Expert Committee On Biological Standardization Geneva, 2016. 15.
  • 8 Holmes H, Davis C, Heath A, Hewlett I, Lelie N. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001; 92(2): 141-150
  • 9 Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. WHO Collaborative Study Group. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001; 80 (01) 63-71
  • 10 Saldanha J, Heath A, Aberham C, Albrecht J, Gentili G, Gessner M, and Pisani G. WHO Collaborative Study to Establish a Replacement WHO International Standard for HCV RNA NAT Assays. WHO/BS/03.1958 Expert Committee on Biological Standardization, Geneva, Feb 17–21; 2003
  • 11 HIV-2 RNA International Standard. (NIBSC code 08/150): Available at:
  • 12 Thadani KB. Public private partnership in the health sector: boon or bane. Procedia Soc Behav Sci 2014; 157: 307-316
  • 13 NACO. A Report on the “Assessment of Blood Banks in Odisha, India”. 2015. 18.
  • 14 Jain R, Aggarwal P, Gupta GN. Need for nucleic acid testing in countries with high prevalence of transfusion-transmitted infections. ISRN Hematol 2012; 2012: 718671
  • 15 Chigurupati P, Murthy KS. Automated nucleic acid amplification testing in blood banks: an additional layer of blood safety. Asian J Transfus Sci 2015; 9 (01) 9-11
  • 16 Pathak S, Chandrashekhar M. Transfusion transmittable infections - seroprevalence among blood donors in a tertiary care hospital of Delhi. Asian J Transfus Sci 2013; 7 (02) 116-118
  • 17 Chigurupati P, Murthy KS. Role of nucleic acid testing in “double” screening of blood donors for a safe blood transfusion. Int J Microbiol Res 2016; 8 (10) 794-796
  • 18 National Viral Hepatitis Control Program Operational Guidelines. [updated 2018; cited October 2021]. Accessed Feb 7, 2022 from:
  • 19 National AIDS Control Organization & ICMR-National Institute of Medical Statistics.. HIV Estimations 2017: Technical Report. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India; 2018
  • 20 Chandra T, Rizvi SNF, Agarwal D. Nucleic acid testing in blood donors of northern India: a single centre experience. International Journal of Contemporary Medical Research 2016; 3 (06) 1818-1821
  • 21 Chandra T, Agarwal D, Rizvi SN. Prevalence of HIV, HCV, HBV infection in blood donors detected by nucleic acid testing: an Indian experience. Eur J Pharm Med Res 2016; 3 (01) 278-292
  • 22 Ghosh K, Mishra K. Nucleic acid amplification testing in Indian blood banks: a review with perspectives. Indian J Pathol Microbiol 2017; 60 (03) 313-318